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INTRODUCTION
Pituitary adenomas comprise 10-15% of all primary brain
tumors and benign tumors usually of slow growth (1). The
goal of management is to improve visual and other neurologi-
cal deficits and to remove as much of the tumor as possible
(2). Complete removal of tumors is infrequent because of the
large size and invasive nature of these tumors. It has been esti-
mated that approximately 50% of patients have tumor rem-
nants after surgery (3). Some authors advocate adjunctive radio-
therapy in the early postoperative period to prevent tumor
recurrence (4, 5). Others prefer individualized treatment re-
commending additional therapy only after demonstration of
unequivocal tumor recurrence or residual symptomatic disease
(6, 7). Ki-67 antigen, which may be detected in all stages of
the cell cycle except G0, represents a marker associated with
tumor proliferation, invasiveness, and ultimately prognosis
(8-10). However, it is still controversial whether Ki-67 is relat-
ed to the aggressive behavior in pituitary adenomas (11). To
assess the relationship between Ki-67 and recurrences, we
used MIB-1 monoclonal antibody to detected the Ki-67 anti-
gen in formalin-fixed, paraffin-embedded tissues (11, 12).
MATERIALS AND METHODS
Patient characteristics 
Between July 1998 and August 2003, 44 patients with
pituitary macroadenoma underwent surgery. In all cases the
Ki-67 labeling index was measured in the surgical specimens
using the MIB-1 monoclonal antibody. The male-to-female
ratio was 1:1.44 (18 males and 26 females). The patients’ age
ranged from 23 to 76 yr (mean 48.9 yr). A functioning ade-
noma, with clinical manifestation of hormonal dysfunction,
was present in 16 patients: 8 with prolactinoma and 8 with
growth hormone (GH) secreting tumor. Visual field defect
was present in 32 patients: 10 with functioning adenoma and
22 with non-functioning adenoma. All patients were classi-
fied according to the Hardy’s classification and were analyzed
in terms of maximal tumor diameter, type of tumor, invasive-
ness, and recurrence. In all cases the neuroradiological diag-
nosis was established.
Ki-67 immunostaining
To determine tumor characteristics at an early stage, we
used MIB-1 antibody to identify the Ki-67 antigen. Surgical-
ly removed specimens were immediately fixed in 10% buffered
formalin and then embedded in paraffin. Ki-67 immunos-
taining was performed using the avidin-biotin-peroxidase
complex method. Five micrometer sections were mounted
onto glass slides, dried, and were incubated with the MIB-1
antibody at 4℃ overnight. The regions with highest con-
centrations of MIB-1 positive nuclei and were selected and
were analyzed at high power magnification (×400). On the
basis of 1,000 neoplastic nuclei, the Ki-67 labeling index was
calculated in each slide as the percentage of immunopositive
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Clinical Significance of Ki-67 Labeling Index in Pituitary Macroadenoma
The aim of our study was to investigate the correlation of the proliferative activity of
pituitary neoplasms with clinical characteristics and recurrences. Tumor specimens
were obtained from 44 consecutive patients with pituitary macroadenomas who
underwent surgery between July 1998 and August 2003. Specimens were imme-
diately fixed in 10% buffered formalin and then embedded in paraffin. The Ki-67
antigen was assessed by immumohistochemical analysis using the monoclonal
antibody. We investigated the correlation of the Ki-67 labeling index with the fol-
lowing clinical and radiological characteristics: sex, age, presence or absence visu-
al field defect, tumor classification, maximal tumor diameter, Hardy’s classification,
type of tumor, invasiveness, and recurrence. Our study suggests that the clinical
characteristics such as visual field defect and recurrence are correlated with the
high Ki-67 labeling index. No statistical differences were observed in the Ki-67
labeling index in relation to the following characteristics: sex, age, tumor classifica-
tion, maximal tumor diameter, Hardy’s classification, type of tumor, and invasive-
ness into the sphenoid sinus or cavernous sinus.
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nuclei. Vascular components and hematogenous cells were
excluded. Only the dark brown stained nuclei were consid-
ered as immunopositive. 
Statistical analysis
Computer assisted data analysis was performed with com-
mercially available software (SPSS 12.0). The independent
samples t-test and ANOVA were used to identify the statis-
tical significance of difference of Ki-67 labeling index ob-
served in relation to the following characteristics: sex, age,
tumor classification, presence or absence of visual field defect,
maximal tumor diameter, Hardy’s classification, type of tumor,
invasiveness to sphenoid or cavernous sinus, and recurrence.
Values are expressed as the mean; for each comparison, a p-
value was obtained and significance was assumed at p<0.05.
RESULTS
Relationship between clinical characteristics and Ki-67
labeling index
The Ki-67 labeling index in 44 pituitary macroadenomas
as detected by using the MIB-1 antibody ranged from 0.1%
to 4%. The mean Ki-67 labeling index was 0.81%. The Ki-67
labeling index was slightly higher in female than in male, but
without a statistical significance (0.84% vs. 0.77%, p=0.821).
The patients’ age at surgery ranged from 23 to 76 yr. The
mean age was 48.9 yr. For statistical analysis, patients’ age at
surgery was classified into six groups: from 21 to 30 yr (n=3),
31 to 40 yr (n=10), 41 to 50 yr (n=14), 51 to 60 yr (n=5),
61 to 70 yr (n=9), and 71 to 80 yr (n=3). The Ki-67 label-
ing index was 1.5%, 0.75%, 1.01%, 0.16%, 0.71%, and
0.73% in each of these age groups, respectively. The younger
patients (21 to 30 yr) had a higher Ki-67 labeling index than
older patients. However, the difference was not statistically
significant (p=0.302). The Ki-67 labeling index was signifi-
No., Number; S.E, standard error; S.D, standard deviation; GH, growth
hormone; p-value <0.05.
No. Ki-67 (Mean) S.E S.D Range p-value
Sex
Male 18 (40.9%) 0.77% 0.2 0.86 0.1-3.5 0.821
Female 26 (59.1%) 0.84% 0.2 1.04 0.1-4.0
Age (yr)
21-30 3 (6.8%) 1.5% 0.97 1.68 0.2-3.4 0.302
31-40 10 (22.7%) 0.75% 0.21 0.68 0.1-2.3
41-50 14 (31.8%) 1.01% 0.34 1.28 0.1-4.0
51-60 5 (11.4%) 0.16% 0.06 0.13 0.1-0.4
61-70 9 (20.5%) 0.71% 0.22 0.66 0.1-2.0
71-80 3 (6.8%) 0.73% 0.38 0.67 0.3-1.5
Visual field defect
Yes 32 (72.7%) 0.99% 0.19 1.06 0.1-4.0 0.042
No 12 (27.3%) 0.33% 0.1 1.06 0.1-1.2
Classification
Nonfunctioning 28 (63.6%) 0.83% 0.19 0.99 0.1-3.5 0.689
Prolactinoma 8 (18.2%) 0.98% 0.45 1.28 0.1-4.0
GH-secreting 8 (18.2%) 0.56% 0.15 0.44 0.1-1.2
Total 44 (100%) 0.81% 0.15 0.96 0.1-4.0
Table 1. Correlation of clinical data and Ki-67 labeling index
Fig. 1. Coronal T1-weighted magnetic resonance (MR) images for radiological invasion of pituitary macroadenoma. Gadolinum-enhanced
coronal image (A) shows a homogeneously enhanced intrasellar mass with invasion into the cavernous sinus. Gadolinum-enhanced
coronal image (B) shows a homogeneously enhanced intrasellar mass without invasion. In adenomas with invasion, the Ki-67 labeling
index was higher than those without invasion.
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cantly higher in pituitary adenomas with visual field defect
than in those without visual field defect (0.99% vs. 0.33%,
p=0.042). As for the hormonal state of the tumors, prolacti-
nomas had a higher Ki-67 labeling index than GH-secret-
ing adenomas, but without a statistical significance (0.98%
vs. 0.56%, p=0.689). The patients’ clinical data are summa-
rized in Table 1.
Relationship between radiological characteristics and 
Ki-67 labeling index
The maximal tumor diameter on magnetic resonance (MR)
image was classified into six groups: from 1.1 to 2.0 cm (n=6),
2.1 to 3.0 cm (n=15), 3.1 to 4.0 cm (n=14), 4.1 to 5.0 cm
(n=7), 5.1 to 6.0 cm (n=1), and 6.1 to 7.0 cm (n=1), with
the Ki-67 labeling index 0.87%, 0.66%, 0.95%, 0.49%,
0.3%, and 3.4% respectively. The difference was not statis-
tically significant (p=0.402). The Hardy’s classification D
(1.08%) had a higher Ki-67 labeling index than the others,
but without a statistical significance (p=0.460). The cystic
type was defined as magnetic resonance (MR) image, T2-
weighted image shows more frequently hypertense signal.
The Ki-67 labeling index was higher in solid type than in
cystic type, but the difference was not statistically significant
(p=0.449). In our cases, invasion was defined as radiological
(MR image) invasion into sphenoid or cavernous sinus (Fig. 1).
Adenomas with invasion had a higher Ki-67 labeling index
(0.86%) than those without invasion (0.78%), but the differ-
ence was not statistically significant (p=0.795). The patients’
radiological data are summarized in Table 2.
Relationship between recurrence and Ki-67 labeling index
Recurrence was defined as the reappearance of hormonal
hypersecretion after normalization of hormone values and
radiological tumor growth. Adenomas with recurrence had
a significantly higher Ki-67 labeling index (1.27%) than
those without recurrence (0.56%) (p=0.027) (Fig. 2). The
No., Number; S.E, standard error; S.D, standard deviation; GH, growth
hormone; p-value <0.05.
No. Ki-67 (Mean) S.E S.D Range p-value
Maximal tumor diameter
1.1-2.0 cm 6 (13.6%) 0.87% 0.54 1.32 0.1-3.5 0.402
2.1-3.0 cm 15 (34.1%) 0.66% 0.26 0.99 0.1-4.0
3.1-4.0 cm 14 (31.8%) 0.95% 0.2 0.75 0.1-2.3
4.1-5.0 cm 7 (15.9%) 0.49% 0.21 0.55 0.1-1.5
5.1-6.0 cm 1 (2.3%) 0.3% 0.3
6.1-7.0 cm 1 (2.3%) 3.4% 3.4
Hardy’s Classification
A 7 (15.9%) 0.29% 0.11 0.29 0.1-0.8 0.460
B 21 (47.7%) 0.97% 0.24 1.11 0.1-4.0
C 9 (20.5%) 0.73% 0.23 0.7 0.1-2.0
D 6 (13.6%) 1.08% 0.49 1.2 0.2-3.4
E 1 (2.3%) 0.1% 0.1
Type
Cyst 19 (43.2%) 0.68% 0.21 0.93 0.1-3.5 0.449
Solid 25 (56.8%) 0.9% 0.2 0.99 0.1-4.0
Invasiveness
Yes 15 (34.1%) 0.86% 0.23 0.9 0.1-3.4 0.795
No 29 (65.9%) 0.78% 0.19 1.01 0.1-4.0
Total 44 (100%) 0.81% 0.15 0.96 0.1-4.0
Table 2. Correlation of radiological data and Ki-67 labeling index
Fig. 2. Immunostaining for Ki-67 in pituitary macroadenoma. Only the dark brown stained nuclei were considered as immunopositive. (A)
The Ki-67 labeling index in recurrent pituitary macroadenoma (3.5%) (original magnification, ×400). (B) The Ki-67 labeling index in non-
recurrent pituitary macroadenoma (1%) (original magnification, ×400). The Ki-67 labeling index was higher in recurrent cases than in
those without recurrence. 
A Bpatients’ recurrence data are summarized in Table 3.
Our study suggests that clinical characteristics such as visual
field defect and recurrence in patients with pituitary macroade-
nomas are significantly correlated with the high Ki-67 label-
ing index. On the other hand, there were no statistical dif-
ference in the Ki-67 labeling index in relation to the follow-
ing characteristics: sex, age at surgery, tumor classification,
maximal tumor diameter, Hardy’s classification, type of tumor,
and invasiveness.
DISCUSSION
Most of the pituitary microadenomas are excised complete-
ly, but it is difficult to totally remove invasive pituitary macro-
adenomas (13). Although most of the pituitary adenomas
grow slowly, some show aggressive or invasive growth (10,
13). Until now, no routine markers have been available to
identify the aggressive behavior of pituitary adenoma. Re-
cently, however, several cell cycle specific nuclear antigens
have been recognized, using various immunohistochemical
methods, which has aided reliable evaluation of tumor growth
characteristics. Among these, Ki-67, a nuclear antigen readily
identified by the monoclonal antibody MIB-1 (14), is typi-
cally expressed in proliferating cells during the G1, S, G2,
and M phases of the cell cycle (15, 16). It has been found to
be useful in assessing several brain tumors, providing infor-
mation about cell proliferation and thus long-term progno-
sis (17, 18). Ki-67 antigen detectable at all stages of the cell
cycle except G0 is considered a useful proliferation marker
(12). The MIB-1 antibody permits detection of the Ki-67
antigen in formalin-fixed, paraffin-embedded tissues. In the
studies by Knosp et al. (15), Zhao et al. (11) and Mastronardi
et al. (17), the mean positive reaction to Ki-67 was 1.1%,
1.4%, and 2.64%, respectively. Generally the Ki-67 label-
ing index in pituitary adenomas is relatively low compared
with other brain tumors (12). With respect to the patient
gender and age, Yonezawa et al. (19) reported a significantly
higher MIB-1 in nonfunctioning adenomas of patients younger
than 30 yr than in patients older than 40 yr. Similarly, Jaf-
frain-Rea et al. (20) reported a significantly higher index in
patients younger than 30 than in older patients. However,
Mastronardi et al. (17) compared different age groups (<25,
between 25 and 50, >50 yr) and found no significant differ-
ence in the Ki-67 index. In the present study, there was no
significant difference in the Ki-67 index among the different
age groups analyzed. Others reported no significant differ-
ences in the Ki-67 index regarding patients gender or tumor
diameter (10, 21). In prolactinomas, Delgrange et al. (22)
found that the indices were likely to be higher in males than
in females, though such difference was not statistically sig-
nificant. Landolt et al. (10) examined the proliferative activ-
ity of 31 pituitary adenomas and reported higher Ki-67 val-
ues for acromegalic patients. In the present series, there was
no significant relationship between the proliferation and hor-
monal states of the adenomas (15). Mindermann and Wilson
(23) analyzed the gender-specific incidence of different types
of pituitary adenomas according to clinical phenotypes and
found that prolactinomas occurred predominantly in females,
while hormonally inactive adenomas and GH-secreting ade-
nomas occurred mainly in males. In the present study, clini-
cally GH-secreting adenomas were predominant in females
(1:1.6), while nonfunctioning adenomas were predominant in
males (1.2:1). Functioning pituitary tumors tend to be more
common among younger adults, whereas nonfunctioning ade-
nomas become more prominent with increasing age (24). The
tumor size, expressed as the maximal diameter measured on
preoperative MR image scans, did not correlate with the Ki-
67 labeling index (7, 21). Hardy (25) classified them into
five type: A) tumor bulging into the chiasmatic cistern; B)
tumor reaching the anterior third ventricle; C) huge suprasel-
lar extension filling the entire third ventricle; D) parasellar
extension into the temporal, frontal, or posterior fossa; and
E) lateral expansion towards the cavernous sinus. Lath et al.
(26) reported a higher Ki-67 labeling index in Hardy’s clas-
sification type E than tumors without extrasellar extension.
The Ki-67 labeling index of the other Hardy’s classification
was not different among the other types. Pituitary adenoma
frequently invade surrounding structures such as the cavernous
sinus, sphenoid sinus, and even the brain (11). Invasive ade-
nomas are not considered to be malignant; their biological
behavior lies between non-infiltrative adenomas and pituitary
carcinomas (27). The reported frequency of invasive pituitary
adenomas varied greatly from 10% to 85%, a reflection of
differenct criteria for the definition of invasiveness. Scheithauer
et al. (27) reported a frequency of 35%. Tumor size did not
correlate with the growth fraction in pituitary adenomas (28),
whereas invasiveness correlated in most studies (2). Indeed,
Gandour-Edwards et al. (29) did not observe any difference
in the Ki-67 labeling indexes between 10 patients with pitu-
itary adenomas involving the sphenoid sinus, and 10 patients
with noninvasive tumors. By contrast, Thapar et al. (30) report-
ed significantly higher Ki-67 labeling indexes of 3% or high-
er to distinguish noninvasive from invasive adenomas. Pitu-
itary adenomas may be associated with a suprasellar exten-
sion, as well outlined by coronal and sagittal MR images.
Tumor invasion leads to neurological complications and also
compromises complete tumor excision and normalization of
hormone levels (1). Residual tumor usually continues to grow,
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No., Number; S.E, standard error; S.D, standard deviation; p-value <0.05.
Recurrence No. Ki-67 (Mean) S.E S.D Range p-value
Yes 14 (31.4%) 1.27% 0.31 1.15 0.1-3.5 0.027
No 30 (68.2%) 0.59% 0.14 0.79 0.1-4.0
Total 44 (100%) 0.81% 0.15 0.96 0.1-4.0
Table 3. Correlation of recurrent data and the Ki-67 labeling
indexbecoming evident as a recurrence with further invasion of
surrounding structures requiring repeat surgery (12). Inva-
sion of the cavernous sinus occurs in 6 to 10% of all pituitary
adenomas (1). Kawamoto et al. (31) reported that adenomas
with invasion of the cavernous sinus had a significantly greater
volume than those without invasion, although they showed
no significant difference in the cell proliferation indexes as-
sessed. Landolt et al. (10) demonstrated a significantly high-
er Ki-67 labeling index in invasive pituitary adenomas (mean
1.15%) than in non-invasive adenomas (mean 0.06%). In
our study, the Ki-67 labeling index in the recurrent group
was higher than in the non-recurrent group. The recurrence
rate of pituitary adenoma has been reported to be as high as
10% to 35% despite their slow growth and benign nature
(32). Incomplete removal of the tumor was one of the most
important causes of recurrence. Ekramullah et al. (13) and
Shibuya et al. (21) reported that they observed higher Ki-67
labeling index values in recurrent adenomas.
In conclusion, the careful clinical, hormonal, and MR image
follow-up is necessary to identify the predicted recurrence of
the tumor as early as possible. The Ki-67 labeling index does
not seem to provide independent information to identify
tumor recurrences. Although studies on the Ki-67 labeling
index from long-term follow-up series are limited, the index
does appear to provide valuable prognostic information. The
high Ki-67 labeling index might suggest the need for care-
ful clinical and radiological follow-up, as a useful marker to
determine the characteristics and recurrence of pituitary ade-
nomas, and therefore on appropriate therapeutic strategy.
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